Remove 2022 Remove BioTech Remove Medicare Remove Pharmaceuticals
article thumbnail

Trust in Healthcare is Under Stress in the US and Globally, Edelman Finds

Health Populi

health citizens’ memories will last into 2022 with respect to cross-party desire for the U.S. to approve Medicare’s negotiation of drug prices with pharmaceutical companies]. The one segment which has stayed relatively even from 2018 has been biotech, 55% that year and 55% again in 2021.

BioTech 310
article thumbnail

Prescription Drugs in the Pandemic, Year 2: Pricing Rx and Going Direct-to-Consumer

Health Populi

health consumers, prescribers, and pharma manufacturers wait on regulation and policy to sort out health politics between now and the 2022 mid-term elections, the private sector (and State Medicaid programs) move at their will and make decisions based on current market conditions and certainties.